5/9/2014 9:04:16 AM
· Research and development costs amounted to SEK 0.4 (0.0) m
· Loss after tax was SEK -1.4 (-1.5) m
· Earnings per share were SEK -0.01 (-0.01)
· The company had no net sales for the period
· ChronTechs therapeutic hepatitis D vaccine activates an immune response that can enter the liver and eliminate liver cells that produce parts of HDV
Help employers find you! Check out all the jobs and post your resume.
comments powered by